Showing results (181-190 of 539) with videos related to

Sort By:
Pageof 54
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)M Jules Mattes, Robert M Sharkey, Habibe Karacay, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|January 11, 2014
Al(18) F labeling of peptides and proteinsPeter Laverman, William J McBride, Robert M Sharkey, et al.
Biology of Reproduction|October 1, 1995
Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryosA M Sharkey, K Dellow, M Blayney, et al.
Journal of Addictive Diseases|February 16, 2010
Insomnia among methadone-maintained individuals: the feasibility of collecting home polysomnographic recordingsMegan E Kurth, Katherine M Sharkey, Richard P Millman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphomaGary L Griffiths, Serengulam V Govindan, Robert M Sharkey, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 8, 2012
Pretargeting: taking an alternate route for localizing radionuclidesRobert M Sharkey, Chien-Hsing Chang, Edmund A Rossi, et al.
Journal of Virology|July 11, 2000
Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responsesK Luzuriaga, M McManus, M Catalina, et al.
Pediatric Dermatology|June 1, 1989
Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocinL L Barton, A D Friedman, A M Sharkey, et al.
Oncotarget|March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
International Journal of Cancer|May 28, 1992
The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumorsO C Boerman, R M Sharkey, R D Blumenthal, et al.
Pageof 54